History of hypersensitivity to durvalumab or tremelimumab or any excipients of these drugs. History of hypersensitivity to tremelimumab, durvalumab, or any excipient History of hypersensitivity to tremelimumab or any excipient Has a history of hypersensitivity to durvalumab or tremelimumab excipient History of hypersensitivity to durvalumab, tremelimumab or any excipient. Willing to have peripheral blood mononuclear cells and bone marrow biopsies to be collected prior to receiving the first dose of durvalumab and tremelimumab, after -doses and -doses of durvalumab and tremelimumab, after nd treatment administration and th treatment administration. History of hypersensitivity to the combination of durvalumab and tremelimumab. History of hypersensitivity to durvalumab or tremelimumab or any excipient Hypersensitivity to durvalumab or tremelimumab, or any excipients on the formulation History of hypersensitivity to tremelimumab or any excipient History of hypersensitivity to durvalumab, tremelimumab, SGI-, or any excipient History of hypersensitivity to durvalumab, tremelimumab, or any excipient. History of hypersensitivity to durvalumab (MEDI), tremelimumab, or any excipient Receipt of the last dose of chemotherapy or tyrosine kinase inhibitors should be at least weeks prior to durvalumab and tremelimumab dosing; monoclonal antibodies such as bevacizumab, ziv-aflibercept, ramucirumab, cetuximab, and panitumumab should be at least weeks prior to durvalumab and tremelimumab therapy History of hypersensitivity to durvalumab, tremelimumab, olaparib or, any excipient History of hypersensitivity to tremelimumab or the combination of MEDI + tremelimumab History of hypersensitivity to durvalumab or tremelimumab or any excipient Treatment with other investigational agent within weeks to the first dose of tremelimumab or durvalumab History of hypersensitivity to durvalumab, tremelimumab or any excipient Patients should agree to not donate blood while participating in this study or for at least days following the last infusion of durvalumab or tremelimumab History of hypersensitivity to tremelimumab History of hypersensitivity to durvalumab, tremelimumab or any excipient Patients should agree to not donate blood while participating in this study or for at least days following the last infusion of durvalumab or tremelimumab